NICORETTE (nicotine polacrilex) by GSK. Approved for nicotine dependence, cigarette smoking behavior. First approved in 1992.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
NICORETTE is a nicotine polacrilex chewing gum indicated for nicotine dependence and cigarette smoking cessation behavior. It works as a cholinergic nicotinic agonist, binding to nicotinic receptors in the brain to reduce cravings and withdrawal symptoms. The buccal delivery format allows patients to self-titrate nicotine intake during the quitting process.
Product approaching loss of exclusivity (2028), signaling transition from brand defense to potential generic/OTC considerations; team size likely scaling back.
Cholinergic Nicotinic Agonist
To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
Clinical Study to Assess Bioequivalence Between Nicorette Extra Mint Gum and Nicorette® Mint Gum in Healthy Smokers
"EASY EFFECTIVE SMOKELESS" With NICORETTE®
Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum
Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment
Worked on NICORETTE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
Working on NICORETTE in 2026 means managing a mature, declining-stage product with limited organic growth and increasing generic competition. Career value lies in crisis management, cost optimization, and defensive marketing rather than innovation or team expansion.